JAZZ PHARMACEUTICAL (J7Z BE) stock market data APIs
€113.181
0(0%)
as of October 13, 2025
Try our APIs with
free plan!
JAZZ PHARMACEUTICAL Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for J7Z.BE.
Prev. Close
113.181
Open
113.181
High
113.181
Low
113.181
52 wk Range
86.72-136.6
Market Cap
6 680 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get JAZZ PHARMACEUTICAL data using free add-ons & libraries
Get JAZZ PHARMACEUTICAL Fundamental Data
JAZZ PHARMACEUTICAL Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
JAZZ PHARMACEUTICAL News
New
Assessing Jazz Pharmaceuticals (JAZZ) Valuation Following Strong Recent Share Price Momentum
Jazz Pharmaceuticals (JAZZ) has caught the attention of investors this month after a steady climb in its stock price, returning about 7% over the past month and 21% in the past 3 months. The consisten...
FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal Phase 3 IMforte trial Zepzelca and atezolizumab combination added to National Comprehensive Can...
Jazz Pharmaceuticals (JAZZ) Gets Price Target Boost Following Positive Xywav Phase 4 Data
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the stocks with low beta that can beat market volatility. On September 23, Morgan Stanley reaffirmed its Overweight rating on Jazz Pharmaceuticals pl...
Headlines Boost Pharma Stocks. Charts of Pfizer, Johnson & Johnson, Jazz Pharmaceuticals Speak to Rally Into Year End
FEATURE Healthcare stocks have found a second wind, with momentum building across biotech and pharmaceuticals. The cleared the very round $100 level for the first time in 10 months yesterday. The more pharma-specific surged 3. Continue Reading View Comments
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
